NP / PA
Ohio Valley Physicians INC
Ohio Valley Physicians INC was paid $43.04M by Medicaid between Jan 2018 and Dec 2024, across 120 billing codes. Its largest line is 80307, Drug test(s), presumptive, any number of drug classes; immunoassay — 32% of everything it billed.
33Billing provider infoOHIO VALLEY PHYSICIANS INC
HUNTINGTON, WV 25703
HUNTINGTON, WV 25703
33aNPI1962433177assigned 07/05/2006
33bProvider typePhysician Assistant
28Total paid$43.04M
24GClaims1,082,741
24DCodes billed120
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Physician Assistant providers in West Virginia
Rank by total paid#1 of 25
Median peer was paid$151K
This provider vs. median285×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 119,366 | $4.16M | |
| 2019 | 140,639 | $4.10M | |
| 2020 | 205,596 | $8.25M | |
| 2021 | 176,520 | $7.66M | |
| 2022 | 157,410 | $6.94M | |
| 2023 | 154,532 | $6.67M | |
| 2024incomplete | 128,678 | $5.26M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 32% | 294,856 | 134,871 | $13.66M |
| G0482 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 15-21 drug class(es), including metabolite(s) if performed | 13% | 49,892 | 35,043 | $5.58M |
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 12% | 136,790 | 72,894 | $5.05M |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | 7.8% | 49,633 | 32,932 | $3.36M |
| 82075 | 6.3% | 169,426 | 83,691 | $2.73M | |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 4.9% | 30,811 | 28,569 | $2.12M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 4.5% | 37,935 | 35,562 | $1.92M |
| G0481 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed | 3.7% | 16,116 | 11,252 | $1.61M |
| 90837 | Psychotherapy session, about an hourPsychotherapy, 53 minutes with patient | 2.5% | 17,102 | 10,721 | $1.09M |
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 1.8% | 15,001 | 10,881 | $759K |
| 81025 | 1.5% | 77,074 | 37,337 | $628K | |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 1.3% | 18,995 | 17,820 | $570K |
108 more codes
| 90832 | Psychotherapy session, about 30 minutes | 1.1% | 13,343 | $485K |
| 90853 | Group psychotherapy (other than of a multiple-family group) | 1.1% | 34,275 | $454K |
| T2023 | Targeted case management; per month | <1% | 1,055 | $312K |
| G0483 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed | <1% | 3,158 | $311K |
| T1015 | A visit at a community health center or clinic (one all-in rate) | <1% | 2,331 | $190K |
| 90834 | Psychotherapy session, about 45 minutes | <1% | 3,856 | $179K |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 5,990 | $176K |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 13,140 | $172K |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 6,305 | $165K |
| T1007 | Alcohol and/or substance abuse services, treatment plan development and/or modification | <1% | 2,728 | $136K |
| 93010 | Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only | <1% | 22,747 | $132K |
| H2036 | Alcohol and/or other drug treatment program, per diem | <1% | 541 | $120K |
| G2087 | Office-based treatment for opioid use disorder, including care coordination, individual therapy and group therapy and counseling; at least 60 minutes in a subsequent calendar month | <1% | 5,024 | $108K |
| 99232 | Hospital visit by a doctor, follow-up day | <1% | 4,788 | $70K |
| 99395 | Periodic comprehensive preventive medicine reevaluation, established patient, 18-39 years | <1% | 968 | $65K |
| 99406 | <1% | 3,378 | $61K | |
| 99396 | Periodic comprehensive preventive medicine reevaluation, established patient, 40-64 years | <1% | 670 | $53K |
| H0031 | Mental health assessment, by non-physician | <1% | 669 | $51K |
| 99202 | Office or other outpatient visit for the evaluation and management of a new patient, straightforward | <1% | 1,219 | $46K |
| H0001 | Alcohol and/or drug assessment | <1% | 1,057 | $41K |
| 80347 | <1% | 1,828 | $38K | |
| 99239 | Hospital discharge day management, more than 30 minutes | <1% | 1,331 | $37K |
| 99222 | Initial hospital care, per day, moderate complexity | <1% | 1,024 | $34K |
| 99385 | <1% | 351 | $33K | |
| 80364 | <1% | 1,828 | $32K | |
| 99291 | Critical care, evaluation and management of the critically ill patient, first 30-74 minutes | <1% | 247 | $21K |
| 1034F | <1% | 2,382 | $21K | |
| 90791 | Psychiatric diagnostic evaluation | <1% | 336 | $20K |
| 99215 | Doctor's office visit, returning patient (complex) | <1% | 274 | $19K |
| 80355 | <1% | 1,862 | $18K | |
| 80348 | <1% | 1,826 | $18K | |
| 80373 | <1% | 1,828 | $18K | |
| 80354 | <1% | 1,821 | $18K | |
| 80368 | <1% | 1,820 | $18K | |
| G2088 | Office-based treatment for opioid use disorder, including care coordination, individual therapy and group therapy and counseling; each additional 30 minutes beyond the first 120 minutes (list separately in addition to code for primary procedure) | <1% | 2,009 | $17K |
| 90792 | Psychiatric diagnostic evaluation with medical services | <1% | 173 | $16K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 1,119 | $16K |
| 80074 | <1% | 510 | $14K | |
| H0004 | Behavioral health counseling and therapy, per 15 minutes | <1% | 282 | $14K |
| 99204 | Doctor's office visit, new patient (more involved) | <1% | 165 | $13K |
| 99203 | Doctor's office visit, new patient (routine) | <1% | 242 | $12K |
| 99386 | <1% | 103 | $12K | |
| 80361 | <1% | 460 | $8K | |
| 80349 | <1% | 790 | $7K | |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 512 | $7K |
| 80369 | <1% | 683 | $7K | |
| 99407 | <1% | 229 | $7K | |
| 80359 | <1% | 679 | $7K | |
| 80339 | <1% | 680 | $7K | |
| 86696 | <1% | 515 | $6K | |
| 36415 | Collection of venous blood by venipuncture | <1% | 1,245 | $6K |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 379 | $5K |
| 80356 | <1% | 475 | $5K | |
| 80324 | <1% | 492 | $5K | |
| 80366 | <1% | 457 | $5K | |
| 80365 | <1% | 457 | $5K | |
| 80061 | Lipid panel | <1% | 474 | $5K |
| 80336 | <1% | 453 | $5K | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 550 | $4K |
| 86695 | <1% | 516 | $4K | |
| 83992 | <1% | 290 | $4K | |
| 82728 | <1% | 448 | $4K | |
| 82607 | <1% | 423 | $4K | |
| 80345 | <1% | 315 | $3K | |
| 82746 | <1% | 415 | $3K | |
| 80353 | <1% | 294 | $3K | |
| 80367 | <1% | 287 | $3K | |
| 99223 | Prolong inpt eval add15 m | <1% | 60 | $3K |
| 80334 | <1% | 284 | $3K | |
| 80358 | <1% | 275 | $3K | |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 599 | $3K |
| 80050 | General health panel | <1% | 59 | $3K |
| 80053 | Comprehensive metabolic panel | <1% | 578 | $3K |
| 99409 | <1% | 123 | $2K | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 190 | $2K |
| 99348 | <1% | 135 | $2K | |
| 99401 | <1% | 109 | $2K | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 101 | $2K |
| 99238 | Hospital discharge day management, 30 minutes or less | <1% | 61 | $2K |
| 80325 | <1% | 182 | $2K | |
| H0049 | Alcohol and/or drug screening | <1% | 132 | $1K |
| 86592 | <1% | 509 | $1K | |
| 99349 | <1% | 53 | $1K | |
| 99490 | Ccm add 20min | <1% | 43 | $1K |
| 99221 | <1% | 54 | $1K | |
| 80305 | <1% | 148 | $1K | |
| 86580 | <1% | 58 | $962.76 | |
| 87807 | <1% | 90 | $843.35 | |
| 96127 | <1% | 131 | $819.52 | |
| 87428 | <1% | 17 | $734.89 | |
| J1030 | Injection, methylprednisolone acetate, 40 mg | <1% | 119 | $689.32 |
| 80076 | <1% | 367 | $619.99 | |
| 99051 | <1% | 182 | $539.35 | |
| 99219 | <1% | 19 | $507.69 | |
| 99441 | <1% | 13 | $413.90 | |
| 82550 | <1% | 85 | $409.18 | |
| 99439 | <1% | 13 | $389.09 | |
| G2012 | Brief communication technology-based service, e.g. virtual check-in, by a physician or other qualified health care professional who can report evaluation and management services, provided to an established patient, not originating from a related e/m service provided within the previous 7 days nor leading to an e/m service or procedure within the next 24 hours or soonest available appointment; 5-10 minutes of medical discussion | <1% | 42 | $334.40 |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 421 | $291.35 |
| 86141 | <1% | 36 | $288.49 | |
| 99217 | <1% | 15 | $244.53 | |
| 85652 | <1% | 77 | $161.70 | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 15 | $78.40 |
| 81002 | <1% | 30 | $71.84 | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 31 | $56.61 |
| 81003 | 0% | 14 | $0.00 | |
| 99000 | 0% | 491 | $0.00 | |
| G0439 | Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | 0% | 28 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialLANDERS, TARA (DIRECTOR OF ACUTE CARE CREDENTIALIN)
| Provider | Location | Paid |
|---|---|---|
| Ohio Valley Physicians INC | Williamson, WV | $4.19M |
| Ohio Valley Physicians, INC | Pikeville, KY | $2.47M |
| Ovp Health Care, INC. | Florence, SC | $139K |
| Ohio Valley Physicians INC | Athens, OH | $11K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.